 |
Ocrelizumab kills the cells that assault the myelin sheath and cause nerve damage Related items from OnMedica NHS England loses appeal over PreP drugs Experts call on regulators to revisit nalmefene decision 75% of reappraised CDF drugs approved for NHS NICE approves extra ‘triple therapy’ drug for diabetes Antibiotic prescribing continues to spiral |
Thursday, 22 December 2016
New multiple sclerosis drug hailed as a 'landmark'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment